文献速递核素与放射性配体治疗

量化周期效应:肽受体放射性核素治疗中后续周期[177Lu]Lu-HA-DOTATATE的肿瘤摄取降低

The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-10-16

该研究基于48例接受多周期[177Lu]Lu-HA-DOTATATE治疗的患者影像数据建立群体药代动力学模型,量化了后续周期中肿瘤摄取降低的周期效应:相比第一周期,第二、三、四周期肿瘤摄取速率分别降至86.9%、79.7%和77.6%。肿瘤体积增大可提高肿瘤摄取速率,持续使用长效生长抑素类似物显著降低脾摄取速率。

要点

  • 相比第一周期,第二、三、四周期肿瘤摄取速率分别降至86.9%、79.7%和77.6%。
  • 肿瘤体积倍增对应肿瘤摄取速率提高2.3倍。
  • 持续使用长效生长抑素类似物时脾摄取为68.4%,显著低于停药时。

核心结论

  • 采用群体药代动力学建模方法量化了后续肽受体放射性核素治疗周期中肿瘤摄取降低的周期效应。
  • 作者认为靶受体下调可能不是周期效应的主要原因,依据是第四周期肿瘤摄取下降出现平台。

研究设计与样本

  • 基于48例接受多周期[177Lu]Lu-HA-DOTATATE治疗患者的影像数据建立群体药代动力学模型。
  • 五室模型包括中央室、肾脏、脾、肿瘤和归并的其余室。
  • 将肿瘤体积和持续使用长效生长抑素类似物作为协变量纳入模型检验。
  • 通过将特定周期的摄取速率表示为第一周期肿瘤或器官摄取速率的分数来评估周期效应。

主要发现

  • 最终药代动力学模型充分捕捉了肾脏、脾和肿瘤中观察到的放射性蓄积。
  • 肿瘤体积较大可提高肿瘤摄取速率,肿瘤体积倍增对应摄取速率提高2.3倍。
  • 持续使用长效生长抑素类似物显著降低脾摄取速率,脾摄取为68.4%,对照为停药时,相对标准误10.5%。
  • 显著识别出周期效应:相比第一周期,第二周期肿瘤摄取速率降至86.9%(相对标准误5.3%),第三周期降至79.7%(相对标准误5.6%),第四周期降至77.6%(相对标准误6.2%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clear evidence regarding the effect of reduced tumour accumulation in later peptide receptor radionuclide therapy (PRRT) cycles is lacking. Therefore, we aimed to quantify potential cycle effects for patients treated with [177Lu]Lu-HA-DOTATATE using a population pharmacokinetic (PK) modelling approach. METHODS: A population PK model was developed using imaging data from 48 patients who received multiple cycles of [177Lu]Lu-HA-DOTATATE. The five-compartment model included a central, kidney, spleen, tumour and lumped rest compartment. Tumour volume and continued use of long-acting somatostatin analogues (SSAs) were tested as covariates in the model. In addition, the presence of a cycle effect was evaluated by relating the uptake rate in a specific cycle as a fraction of the (tumour or organ) uptake rate in the first cycle. RESULTS: The final PK model adequately captured observed radioactivity accumulation in kidney, spleen and tumour. A higher tumour volume was identified to increase the tumour uptake rate, where a twofold increase in tumour volume resulted in a 2.3-fold higher uptake rate. Also, continued use of long-acting SSAs significantly reduced the spleen uptake rate (68.4% uptake compared to SSA withdrawal (10.5% RSE)). Lastly, a cycle effect was significantly identified, where tumour uptake rate decreased to 86.9% (5.3% RSE) in the second cycle and even further to 79.7% (5.6% RSE) and 77.6% (6.2% RSE) in the third and fourth cycle, respectively, compared to cycle one. CONCLUSIONS: Using a population PK modelling approach, the cycle effect of reduced tumour uptake in subsequent PRRT cycles was quantified. Our findings implied that downregulation of target receptors is probably not the major cause of the cycle effect, due to a plateau in the decrease of tumour uptake in the fourth cycle.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Siebinga H, Hendrikx JJMA, de Vries-Huizing DMV, et al. The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2023. PMID: 37843598. doi:10.1007/s00259-023-06463-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。